Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
Oncoimmunology, 2014•Taylor & Francis
Targeting immune inhibitory receptors has brought excitement, innovation and hope to
cancer patients. Our recent work revealed the immunological effects of blocking the CTLA4
and PD-1 immune checkpoints on T cell receptor usage among peripheral blood cells, and
further uncovers how the expansion of the T cell repertoire matches the immunotoxicity
profile of the therapy.
cancer patients. Our recent work revealed the immunological effects of blocking the CTLA4
and PD-1 immune checkpoints on T cell receptor usage among peripheral blood cells, and
further uncovers how the expansion of the T cell repertoire matches the immunotoxicity
profile of the therapy.
Targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients. Our recent work revealed the immunological effects of blocking the CTLA4 and PD-1 immune checkpoints on T cell receptor usage among peripheral blood cells, and further uncovers how the expansion of the T cell repertoire matches the immunotoxicity profile of the therapy.
Taylor & Francis Online